The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|April 1, 2020
Daiichi Sankyo Enters Partnership with Ultragenyx for a Total of $225 Million
Author(s)Pharmaceutical Technology Editors
Daiichi Sankyo has entered into a partnership with Ultragenyx Pharmaceutical for the use of Ultragenyx’s proprietary AAV-based gene-therapy manufacturing technology.
Advertisement
Daiichi Sankyo, a pharmaceutical company based in Japan, announced on April 1, 2020 that it has entered into a partnership with Ultragenyx Pharmaceutical, a clinical-stage biopharmaceutical company located in Novato, CA, for use of Ultragenyx’s proprietary adeno associated virus (AAV)-based gene therapy manufacturing technology.
Through the agreement, Daiichi Sankyo will provide an upfront payment of $125 million to Ultragenyx along with additional payments of $25 million for technology transfer and sales royalties of products manufactured by Ultragenyx’s technology, and $75 million for Ultragenyx’s common stock, a Daiichi Sankyo press release said.
Following the technology transfer, Daiichi Sankyo plans to expand its manufacturing capacity by starting the manufacture of investigational drugs for AAV gene therapy by the middle of 2020 with Ultragenyx’s assistance, according to the press release.
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement